(R)-SL18

(R)-SL18: sourced facts only. name: "(R)-SL18 directly bound to ANXA3 and increased its ubiquitination, thereby inducing ANXA3 degradation with moderate family selectivity." [PMID:37139408]; target: "(R)-SL18 directly bound to ANXA3 and increased its ubiquitination, thereby inducing ANXA3 degradation with moderate family selectivity." [PMID:37139408]; developer: "School of Pharmacy, Fudan University, Shanghai 201203, China." [PMID:37139408]; modality: "Herein, we report a first-in-class ANXA3-targeted small molecule (R)-SL18, which demonstrated excellent anti-proliferative and anti-invasive activities to TNBC cells." [PMID:37139408]; stage: "Importantly, (R)-SL18 showed a safe and effective therapeutic potency in a high ANXA3-expressing TNBC patient-derived xenograft model." [PMID:37139408]